Nuclear Medicine Radioisotopes Global Market to Observe Highest Growth of $11.44 Billion with an Excellent CAGR of 10.7% by 2028 | Bayer AG, Curium Pharma, Radiomedix Inc., Positron Corporation

The nuclear medicine radioisotopes from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Nuclear Medicine Radioisotopes Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size –
The nuclear medicine radioisotopes market size has grown strongly in recent years. It will grow from $7.57 billion in 2023 to $8.21 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to discovery of radioactivity, emergence of nuclear medicine, therapeutic applications, clinical research, and patient demand.

The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $11.44 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing healthcare spending, expansion of healthcare infrastructure, growing awareness of environmental sustainability, education campaigns and awareness programs and growth in medical tourism. Major trends in the forecast period include development of new radioisotopes, production and supply chain innovations, microfluidics and lab-on-a-chip technology, artificial intelligence in radiopharmaceutical development and nanotechnology.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report

Scope Of Nuclear Medicine Radioisotopes Market
The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Nuclear Medicine Radioisotopes Market Overview

Market Drivers –
The rising cases of cardiovascular diseases are expected to propel the growth of the nuclear medicine radioisotope market going forward. Cardiovascular diseases refer to a group of diseases that affect the heart and blood vessels. The rising cases of cardiovascular diseases are due to sedentary lifestyles, poor dietary habits, increasing rates of obesity, and aging populations. The nuclear medicine radioisotopes are invaluable in diagnosing, evaluating, and managing cardiovascular diseases with detailed insights into cardiac function, perfusion, and tissue viability, which are essential for accurate diagnosis and effective treatment planning. For instance, in May 2022, according to the Centers for Disease Control and Prevention, a US-based governmental organization, the prevalence of coronary heart disease among adults aged 18 and over stood at 4.6% in 2020, experiencing a slight uptick to 4.9% in 2021. Therefore, the rising cases of cardiovascular diseases are driving the growth of the nuclear medicine radioisotope market.

Market Trends –
Major companies operating in the nuclear medicine radioisotopes market are focusing on developing innovative products, such as the compact low-energy cyclotron, to improve the production and availability of radioisotopes, ensuring more efficient and accessible diagnostic and therapeutic options. A compact, low-energy cyclone is a small particle accelerator used to create radioisotopes for medical imaging and treatments in nuclear medicine. For instance, in January 2022, IBA, a Belgium-based provider of radiopharmaceutical production solutions, launched Cyclone Key, a new accelerator providing increased access to diagnostic solutions and enabling in-house production of radiopharmaceuticals. This innovative solution offers unique features such as a compact and efficient design, fully automated operation, multiple isotope production capabilities, ease of installation and operation, water cooling, self-shielding, and high performance, making it versatile and reliable.

The nuclear medicine radioisotopes market covered in this report is segmented –
1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Actinium-225 (Ac-225), Other Types
2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users

Get an inside scoop of the nuclear medicine radioisotopes market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp

Regional Insights –
North America was the largest region in the nuclear medicine radioisotopes market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies –
Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer Aktiengesellschaft, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacıbaşı-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Table of Contents
1. Executive Summary